Aktis Oncology, Inc. (AKTS) Investor Relations Documents

Aktis Oncology, Inc. (AKTS) investor relations documents from the company's IR site: 4 presentations, 36 press releases; latest deck 2026-06-10. Read in-app with summaries. First-party data.

View Presentation: Aktis Oncology is developing a miniprotein radioconjugate platform for cancer, with lead programs AKY-1189 and AKY-2519 targeting Nectin-4 and B7-H3.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releasePDF Version
2026-08-13Press releaseAktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
2026-06-10PresentationView Presentation
2026-05-27PresentationView Presentation
2026-05-27Press releasePDF Version
2026-05-27Press releaseAktis Oncology to Present at the Jefferies Global Healthcare Conference
2026-05-21Press releasePDF Version
2026-05-21Press releaseAktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake
2026-05-11Press releasePDF Version
2026-05-11Press releaseAktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
2026-05-06Press releasePDF Version
2026-05-06Press releaseAktis Oncology to Present at the BofA Securities Health Care Conference
2026-05-05PresentationView Presentation
2026-05-04Press releasePDF Version
2026-05-04Press releaseAktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castrat
2026-04-21Press releasePDF Version
2026-04-21Press releaseAktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Soc
2026-04-16Press releasePDF Version
2026-04-16Press releaseAktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
2026-03-30Press releasePDF Version
2026-03-30Press releaseAktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updat
2026-03-02PresentationView Presentation
2026-02-24Press releasePDF Version
2026-02-24Press releasePDF Version
2026-02-24Press releaseAktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
2026-02-24Press releaseAktis Oncology to Present at Upcoming March Investor Conferences
2026-01-13Press releasePDF Version
2026-01-13Press releaseAktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchas
2026-01-08Press releasePDF Version
2026-01-08Press releaseAktis Oncology Announces Pricing of its Upsized Initial Public Offering
2025-11-05Press releasePDF Version
2025-11-05Press releaseAktis Oncology Appoints Kyle Kuvalanka Chief Financial Officer
2025-09-10Press releaseAktis Oncology to Participate in Upcoming September Investor Conferences
2025-08-07Press releasePDF Version
2025-08-07Press releaseAktis Oncology Appoints Accomplished Life Sciences Industry Veteran Mike Sherman to its Board of Directors
2025-05-28Press releasePDF Version
2025-05-28Press releaseAktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1
2025-02-25Press releasePDF Version
2025-02-25Press releaseAktis Oncology to Participate in the 45th annual TD Cowen Healthcare Conference
2025-02-04Press releasePDF Version

AKTS overview · AKTS earnings · AKTS financials · AKTS KPIs · AKTS documents · AKTS ownership · AKTS peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.